China and Japan to hold maritime dialogue despite espionage allegations and executive arrest.
The CEO of Japanese pharmaceutical company Eisai has ruled out exiting the Chinese market following the arrest of a Chinese executive on suspicion of spying. The company will instead focus on strengthening its compliance and risk management systems in China. Eisai has been operating in China for over 30 years and sees the country as a key market for growth.